Characteristics of 190 Children With Newly Diagnosed ALL of Whom Material Was Received for In Vitro Cellular Drug-Resistance Testing, Divided in Patients in Whom Such Testing Was Successful (n = 152) and in Whom It Was Not (n = 38)
| . | Assay Successful . | Assay Unsuccessful . | P Value . |
|---|---|---|---|
| No. of patients | 152 | 38 | |
| Age in mo, median (range) | 61 (2-190) | 48 (15-178) | .17 |
| Female/male ratio | 65:87 | 14:24 | .51 |
| WBC × 109/L, median (range) | 22.9 (0.5-746) | 8.5 (1.3-178) | .007 |
| BFM risk factor,* median (range) | 1.06 (0.31-2.03) | 0.85 (0-2.05) | .001 |
| FAB type | .44 | ||
| L1 | 123 | 32 | |
| L2 | 28 | 5 | |
| AUL† | 1 | 1 | |
| Immunophenotype | .40 | ||
| Pro-B | 6 | 3 | |
| Common | 77 | 23 | |
| Pre-B | 38 | 7 | |
| T | 31 | 5 | |
| DNA ploidy | <.0001‡ | ||
| Nonhyperdiploid | 119 | 18 | |
| Hyperdiploid | 18 | 16 | |
| Unknown | 15 | 4 | |
| DCLSG protocol VII/VIII | 80/72 | 20/18 | 1.0 |
| Risk group | .03 | ||
| Low | 38 | 16 | |
| Medium | 99 | 16 | |
| High | 15 | 6 | |
| Follow-up, median (range) (in mo) | 46 (17-81) | 51 (29-81) | .77 |
| Events | .04 | ||
| No CR | 1 | 0 | |
| Relapse | 44 | 5 | |
| Early death | 2 | 0 | |
| Toxic death | 3 | 1 | |
| No event | 102 | 32 | |
| pDFS (%) | .04 | ||
| 3 yr (SE) | 73 (4) | 89 (6) | |
| 4 yr (SE) | 68 (6) | 85 (8) |
| . | Assay Successful . | Assay Unsuccessful . | P Value . |
|---|---|---|---|
| No. of patients | 152 | 38 | |
| Age in mo, median (range) | 61 (2-190) | 48 (15-178) | .17 |
| Female/male ratio | 65:87 | 14:24 | .51 |
| WBC × 109/L, median (range) | 22.9 (0.5-746) | 8.5 (1.3-178) | .007 |
| BFM risk factor,* median (range) | 1.06 (0.31-2.03) | 0.85 (0-2.05) | .001 |
| FAB type | .44 | ||
| L1 | 123 | 32 | |
| L2 | 28 | 5 | |
| AUL† | 1 | 1 | |
| Immunophenotype | .40 | ||
| Pro-B | 6 | 3 | |
| Common | 77 | 23 | |
| Pre-B | 38 | 7 | |
| T | 31 | 5 | |
| DNA ploidy | <.0001‡ | ||
| Nonhyperdiploid | 119 | 18 | |
| Hyperdiploid | 18 | 16 | |
| Unknown | 15 | 4 | |
| DCLSG protocol VII/VIII | 80/72 | 20/18 | 1.0 |
| Risk group | .03 | ||
| Low | 38 | 16 | |
| Medium | 99 | 16 | |
| High | 15 | 6 | |
| Follow-up, median (range) (in mo) | 46 (17-81) | 51 (29-81) | .77 |
| Events | .04 | ||
| No CR | 1 | 0 | |
| Relapse | 44 | 5 | |
| Early death | 2 | 0 | |
| Toxic death | 3 | 1 | |
| No event | 102 | 32 | |
| pDFS (%) | .04 | ||
| 3 yr (SE) | 73 (4) | 89 (6) | |
| 4 yr (SE) | 68 (6) | 85 (8) |